We determined levels of antibodies and autoantibodies in terminal serum taken at 18-20 weeks of age for the IP cohort and found that total IgG levels were not significantly different between the anti-CXCL13 and isotype control treated groups (p=0.41) (Figure 1A). This evidence concerns the gene CXCL13 and incontinentia pigmenti.